A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

The purpose of the study is to compare the efficacy and safety of SYS6010 in combination with anti-PD-(L)-1 monoclonal antibody vs. anti-PD-(L)-1 monoclonal antibody as adjuvant therapy for patients with. with completely resected stage II-IIIB, actionable genomic alterations (AGAs) negative non-small cell lung cancer (NSCLC) who did not achieve a major pathological response (MPR).

NCT Number	NCT07672223
Lead Sponsor	CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions	Non-small Cell Lung Cancer
Enrollment	570 participants
Start Date	2026-06-25
Primary Completion	2029-09-30 (estimated)
Study Completion	2031-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-26